Pancreatic Cancer Research

ResearcherUniversitat de GironaActive in the last 2 years

Pedro Enrique Guerrero

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2612-9235; OpenAlex author ID A5088986209. Sources: OpenAlex.

Their work

Papers
10 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 2 papers · 2025: 1 paper

Papers 10

  1. Quantitative characterization of the 3D self-organization of PDAC tumor spheroids reveals cell type and matrix dependence through advanced microscopy analysis. Last author DOI 10.1063/5.0242490↗
  2. Physico-chemical characterization of the tumour microenvironment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejcb.2024.151396↗
  3. Polydopamine Interfacial Coating for Stable Tumor-on-a-Chip Models: Application for Pancreatic Ductal Adenocarcinoma. First author DOI 10.1021/acs.biomac.4c00551↗
  4. Characterization of Mesothelin Glycosylation in Pancreatic Cancer: Decreased Core Fucosylated Glycoforms in Pancreatic Cancer Patients' Sera. First author DOI 10.3390/biomedicines10081942↗
  5. Sialyltransferase Inhibitor Ac53FaxNeu5Ac Reverts the Malignant Phenotype of Pancreatic Cancer Cells, and Reduces Tumor Volume and Favors T-Cell Infiltrates in… Co-author DOI 10.3390/cancers14246133↗
  6. Microfibril associated protein 4 (MFAP4) is a carrier of the tumor associated carbohydrate sialyl-Lewis x (sLe x) in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.jprot.2020.104004↗
  7. Knockdown of α2,3-Sialyltransferases Impairs Pancreatic Cancer Cell Migration, Invasion and E-selectin-Dependent Adhesion. Co-author DOI 10.3390/ijms21176239↗
  8. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. Co-author DOI 10.1073/pnas.1722434115↗
  9. Glycoprotein biomarkers for the detection of pancreatic ductal adenocarcinoma. First author DOI 10.3748/wjg.v24.i24.2537↗
  10. The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer. First author DOI 10.18632/oncotarget.10199↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. José Manuel García‐Aznar · 3 shared papers, 2024–2025 · strength 0.82
  2. Neus Martínez‐Bosch · 5 shared papers, 2016–2025 · strength 0.68
  3. Pilar Navarro · 5 shared papers, 2016–2025 · strength 0.68
  4. Esther Llop Escorihuela · 5 shared papers, 2018–2022 · strength 0.64
  5. Rosa Peracaula Miró · 5 shared papers, 2018–2022 · strength 0.64
  6. Soraya Hernández-Hatibi · 2 shared papers, 2024–2025 · strength 0.61
  7. Elena García‐Gareta · 2 shared papers, 2024 · strength 0.51
  8. Adrià Duran · 3 shared papers, 2018–2022 · strength 0.38
  9. Adelaida Garcia-Velasco · 2 shared papers, 2021–2022 · strength 0.29
  10. Laura Miró · 2 shared papers, 2020–2022 · strength 0.26
  11. Patricia Sancho Andrés · 1 shared paper, 2024 · strength 0.20
  12. Noemí Manero‐Rupérez · 1 shared paper, 2022 · strength 0.15
  13. Carlos A. Orozco Castaño · 2 shared papers, 2016–2018 · strength 0.12
  14. Judith Vinaixa · 2 shared papers, 2016–2018 · strength 0.12
  15. Κωνσταντίνος Κωνσταντόπουλος · 1 shared paper, 2020 · strength 0.11
  16. Bin Sheng Wong · 1 shared paper, 2020 · strength 0.11
  17. María José Ferri · 1 shared paper, 2018 · strength 0.08
  18. Rosa F. Hwang · 1 shared paper, 2018 · strength 0.07
  19. Carmen E. Guerra · 1 shared paper, 2018 · strength 0.07
  20. Martín E. Fernández-Zapico · 1 shared paper, 2018 · strength 0.07
  21. Cristina Fillat Fonts · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.